| 张巍巍 沈磊 耿长新 许琳 赵丽萍 孙昕 邹瑞珍 王园园 王颖 王青.S-腺苷蛋氨酸治疗胆汁淤积性肝病伴抑郁/焦虑的临床效果研究[J].现代生物医学进展英文版,2014,14(19):3740-3743. |
| S-腺苷蛋氨酸治疗胆汁淤积性肝病伴抑郁/焦虑的临床效果研究 |
| Research on S-adenosylmethionine in the Treatment of Patients of CholestaticLiver Diseases Associated with Anxiety/depression |
| |
| DOI： |
| 中文关键词: 胆汁淤积 焦虑 抑郁 S- 腺苷蛋氨酸 |
| 英文关键词: Cholestasis Anxiety Depression S-adenosylmethionine |
| 基金项目:青岛市科技发展计划项目(11-2-3-2-c81-nsh) |
|
| Hits: 814 |
| Download times: 1096 |
| 中文摘要: |
| 目的：研究S- 腺苷蛋氨酸治疗胆汁淤积性肝病伴抑郁/ 焦虑患者的临床效果。方法：选择2011 年3 月～2013 年3月我院收
治的51 例不同病因的胆汁淤积性肝病(药物性肝损害13 例、慢性乙型肝硬化14 例、酒精性肝硬化11 例、自身免疫性肝病6例、
肝癌5 例、胆管癌2例)并抑郁/焦虑的患者，予S-腺苷蛋氨酸1.0 g 治疗2 周，应用SDS/SAS量表分别评估和比较治疗前后各组
患者抑郁/ 焦虑程度的评分情况。结果：S- 腺苷蛋氨酸治疗后，所有组别胆汁淤积性肝病肝病改善的临床总有效率94.12%，其中
药物性肝损害、慢性乙型肝硬化、酒精性肝硬化、自身免疫性肝硬化总有效率均为100.00%，肝癌的有效率为60.00%，胆管癌的有
效率为50.00%，药物性肝损害患者临床疗效与其他各组有差异(P＜0.05)；药物性肝病患者SDS 和SAS 评分均较治疗前显著降低
(P<0.05)。而慢性乙型肝硬化、酒精性肝硬化、自身免疫性肝病、肝癌、胆管癌患者SDS和SAS评分与治疗前相比均无统计学差异
(P>0.05)。结论：S-腺苷蛋氨酸可改善药物性胆汁淤积性肝病并轻、中度抑郁/ 焦虑患者的肝功能，并有效减轻其抑郁/ 焦虑情绪。 |
| 英文摘要: |
| Objective:To study the clinical effects of S-adenosyl methionine for patients with cholestatic liver disease associated
with depression or anxiety.Methods:51 patients with different causes of cholestatic liver diseases (13 cases of drug-induced liver injury,
14 cases of chronic hepatits B cirrhosis, 11 cases of alcoholic cirrhosis, 6 cases of autoimmune liver disease, 5 cases of hepatocellular
carcinoma and 2 cases of cholangiocarcinoma) and depression or anxiety were selected in our hospital from March 2011 to March 2013
and treated with intravenous use of S-adenosyl methionine 1.0 g for 2 weeks. Then, Zung's SDS / SAS assessment were applied to
compare the effects in these groups.Results:After treatment with S-adenosylmethionine, the total effetive ratio of all cholestatic liver
diseases was 94.12%, including 100.00% in drug-induced liver injury, chronic hepatits B cirrhosis, alcoholic cirrhosis and autoimmune
liver disease, 60.00% in hepatocellular carcinoma and 50.00% in cholangiocarcinoma. There was significant statistical differences
between drug-induced cholestatic liver disease and the other groups (P<0.05). Scores of SDS and SAS significantly decreased in patients
with drug-induced cholestatic liver disease after treated with S-adenosylmethionine (P<0.05), however, it seemed no change in chronic
cholestatic liver disease (cirrhosis, autoimmune liver disease) as well as in hepatobiliary cancer (hepatocellular carcinoma,
cholangiocarcinoma) .Conclusion:S-adenosylmethionine could improve the liver function in patients with drug-induced cholestatic liver
disease associated with mild and moderate depression or anxiety, and effectively better their depressive or anxious mood. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
